Abstract
This study determined the unbound fraction of the peripheralα2‐adrenoceptor antagonistMK‐467 alone and combined with medetomidine.MK‐467 (0.1, 1 and 10 μm) was incubated in canine plasma with and without medetomidine (molar ratio 20:1), with human serum albumin (HSA) and withα1‐acid glycoprotein (AGP). Rapid equilibrium dialysis was used for the measurement of protein binding. All samples were analysed by liquid chromatography and tandem mass spectrometry to obtain the unbound fraction (fu) ofMK‐467. Unbound fractions (fu) ofMK‐467 in canine plasma (mean ± standard deviation) were 27.6 ± 3.5%, 26.6 ± 0.9% and 42.4 ± 1.2% at 0.1, 1.0 and 10 μmconcentrations, respectively. In the presence of medetomidine,fuwere 27.5 ± 0.4%, 26.6 ± 0.9% and 41.0 ± 2.4%. ThefuofMK‐467 inHSAwere 50.1 ± 2.5% at 0.1 μm, 49.4 ± 1.2% at 1.0 μmand 56.7 ± 0.5% at 10 μm.fuofMK‐467 inAGPwas 56.3 ± 3.7% at 0.1 μm, 54.6 ± 5.6% at 1.0 μmand 65.3 ± 0.4% at 10 μm. Protein binding ofMK‐467 was approximately 70% between 0.1 and 1.0 μm. Medetomidine had no apparent effect on the protein binding ofMK‐467.
Funding Information
  • Vetcare Ltd
  • ANIWEL graduate school, University of Helsinki, Finland

This publication has 14 references indexed in Scilit: